Oxelidine fumarate injection for painless gastroscope in 90% minimum dose: biased coin method

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400092318

Enrollment

Unknown

Registered

2024-11-14

Start date

2024-11-20

Completion date

Unknown

Last updated

2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Experimental group:The first patient was given Oxalidine Fumarate Injection 20ug/Kg and Propofol Injection 2mg/Kg. The next patient has an 11% probability of reducing a dose gradient (2ug/Kg), and an

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Patients of both sexes, aged 18-64 years, with body mass index (BMI) of 18-28 kg/m2, were of American Society of Anesthesiologists (ASA) physical status ? or ?

Exclusion criteria

Exclusion criteria: Allergy to narcotic drugs, abuse of sedatives or analgesics, mental illness, pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
inhibiting responses to gastroscope insertion;	—

Countries

China

Contacts

Public ContactZhiyong Tang

The First Affiliated Hospital of Dali University

1041312893@qq.com+86 135 9418 4525

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026